A New Frontier in Tumor Eradication: Harnessing In Vivo Cellular Reprogramming for Durable Cancer Immunotherapy

Cell Reprogram. 2024 Oct;26(5):132-134. doi: 10.1089/cell.2024.0077. Epub 2024 Oct 10.

Abstract

Tumors evade immune detection by downregulating antigen presentation and hindering immune responses. Type 1 conventional dendritic cells (cDC1s) are vital in stimulating cytotoxic T cells against tumors. Ascic et al. are now demonstrating the in situ ability of PU.1, IRF8, and BATF3 (PIB) transcription factors to directly reprogram a plethora of tumors bypassing the suppressive effects of the tumor microenvironment, and leading to overall tumor regression while eliciting a systemic immune response that can protect from secondary tumor induction.

Keywords: PIB; cDC1; immunotherapy; in situ reprogramming.

Publication types

  • News

MeSH terms

  • Animals
  • Basic-Leucine Zipper Transcription Factors / genetics
  • Basic-Leucine Zipper Transcription Factors / immunology
  • Basic-Leucine Zipper Transcription Factors / metabolism
  • Cellular Reprogramming*
  • Dendritic Cells / immunology
  • Humans
  • Immunotherapy* / methods
  • Interferon Regulatory Factors / genetics
  • Interferon Regulatory Factors / metabolism
  • Neoplasms* / immunology
  • Neoplasms* / therapy
  • Proto-Oncogene Proteins / genetics
  • Trans-Activators / genetics
  • Tumor Microenvironment

Substances

  • Basic-Leucine Zipper Transcription Factors
  • BATF3 protein, human
  • interferon regulatory factor-8
  • Interferon Regulatory Factors
  • proto-oncogene protein Spi-1
  • Proto-Oncogene Proteins
  • Trans-Activators